Altered ARID1A expression in colorectal cancer

Area of Science:

• Oncology
• Molecular Biology
• Epigenetics

Background:

• ARID1A functions as a tumor suppressor gene involved in chromatin remodeling and epithelial-mesenchymal-transition.
• Its precise role in colorectal cancer (CRC) tumorigenesis remains undefined.
• Understanding ARID1A's function in CRC is crucial for developing targeted therapies.

Purpose of the Study:

• To investigate the role of ARID1A methylation and copy number variation (CNV) in its expression within CRC cell lines.
• To examine the correlation between ARID1A status and patient survival and clinicopathological characteristics in CRC.
• To elucidate the impact of DNA demethylation on ARID1A expression.

Main Methods:

• ARID1A copy number variation (CNV) and mRNA expression were determined using RT-PCR in six CRC cell lines.
• ARID1A promoter methylation was assessed via methylation-specific PCR (MSP).
• ARID1A protein expression was evaluated by immunohistochemistry (IHC), and its response to 5-aza-2'-deoxycytidine (5-aza) treatment was analyzed.

Main Results:

• ARID1A expression was downregulated in 38.8% and 27.7% of 18 CRC tumors, respectively.
• Promoter methylation was observed in 66% of CRC cell lines, correlating with reduced ARID1A mRNA levels.
• 5-aza treatment increased ARID1A mRNA expression in specific cell lines, indicating a role for DNA methylation in its regulation. No ARID1A CNV was detected.
• Lymphatic invasion was more frequent in tumors with low/no ARID1A expression.

Conclusions:

• ARID1A is downregulated in CRC, supporting its role as a tumor suppressor in CRC development.
• In vitro findings suggest that promoter methylation contributes to reduced ARID1A expression and CRC tumorigenesis.
• No significant association was found between ARID1A expression levels and overall survival or most clinicopathological parameters, warranting further in vivo studies.